Novavax | NVAX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Adma Biologics USD 3.42M 1.32M 2026-06
Agenus USD 14.67M 1.35M 2026-03
AstraZeneca USD 371M 31M 2026-09
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Cassava Sciences USD 100.06M 99.31M 2026-09
Geron USD 7.21M 61K 2026-09
GlaxoSmithKline GBP 219M 98M 2026-09
MannKind USD 10.58M 4.24M 2026-09
Merck USD 525M 46M 2026-06
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 10.96B 527M 2026-06
Novartis USD 281M 8M 2025-09
Novavax USD 5.82M 342K 2025-12
Pfizer USD 662M 5M 2026-09
Sanofi EUR 222M 65M 2026-09
Sarepta Therapeutics USD 21.51M 205K 2026-06
TG Therapeutics USD 16.57M 8.91M 2026-06